common.study.topics.clinical

Testing Treatment for Prostate Cancer

common.study.values.description

A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

The purpose of this study is to establish the recommended phase 2 dose (RP2D) of niraparib combination therapies of Part 1 and to evaluate the antitumor activity and safety of niraparib combination therapies of Part 2.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - Niraparib 200 mg

Participant will receive niraparib 200 mg orally once daily.

Drug - Cetrelimab mg

Participants will receive cetrelimab 240 mg IV every 2 weeks.

Drug - Cetrelimab 480 mg

Participants will receive cetrelimab 480 mg IV every 4 weeks.

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

common.study.values.clinical-trial-id

NCT03431350

participant.views.study.view.id

lejoBa